SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) April 12, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) ( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On April 12, 1996, Biocontrol Technology, Inc.
announced today that at a special meeting held
yesterday, April 11, at the Westin William Penn Hotel,
Pittsburgh, PA, shareholders overwhelmingly supported
the Company's request to increase by 20,000,000 the
number of authorized shares of common stock.
As of the record date, February 5, 1996, BICO had
39,730,618 outstanding shares of stock. Previous to
the shareholders' meeting, 35,258,374 shares voted by
proxy in favor of the authorization; at the meeting
873,200 additional shares voted to authorize the
request for a total vote to pass of 36,131,574 (91% of
shares outstanding). By proxy, only 2,433,632 shares
voted against the requested share increase
(approximately 6% of eligible shares).
Biocontrol has recently reported that it has
plenty of cash to fund additional necessary testing on
its Diasensor 1000 noninvasive glucose sensor for
diabetics, which is currently in the Food and Drug
Administration (FDA) approval process. Additional
funding will be necessary, however, as increased
inventory is needed to begin production of the device.
Currently, laboratory testing of assembled
production units is underway. By early May, Biocontrol
expects to have 30 such sensors completed, 20 of which
will be used for patient testing.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: April 12, 1996
